Fusion

Hamilton, Ontario and Boston.  June 14, 2021.    Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preliminary Phase 1 data from the single-dose portion […]

Hamilton, Canada and Boston, USA.  May 6, 2021.  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration […]

Hamilton, ON and Boston.  April 1, 2021.   Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines today announced the appointment of Donald A. Bergstrom, M.D., Ph.D., as a […]

Hamilton, Canada and Boston, USA.  March 2, 2021.  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced it has entered into an asset purchase agreement (APA) […]

Hamilton, Ontario and Boston. 10 December 2020.  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the first patient has been dosed in the multi-dose […]

Hamilton, Ontario and Boston, 2 November 2020.  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop and commercialize […]

Hamilton, Ontario and Boston.  25 June 2020.  Fusion Pharmaceuticals Inc. (NASDAQ: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the pricing of its initial public offering of 12,500,000 common […]

Hamilton, Ontario.  23 March 2020.  Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines to treat a broad range of cancers, today announced the appointment of James […]

Boston, Massachusetts & Hamilton, Ontario.  February 6, 2020.   Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing targeted alpha therapeutics, has announced the appointment of Pablo J. Cagnoni, M.D., to the board […]

Hamilton, Ontario & Boston, Massachusetts.  January 13, 2020.  Seroba’s portfolio company, Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, today announced an investment commitment of up to US$20 million from Canada Pension Plan […]

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top